96 results about "Cancer suppressor gene" patented technology

The invention discloses a cancer chemosensitivity prediction technique based on a molecular subnet and a random forest classifier. The method is characterized by comprising the steps of fusing data of oncogene expression profile, information of tumor mutation genome information and information of protein-protein interaction group, and excavating carcinogenic and cancer suppressor gene molecular subnets to realize feature extraction; taking the feature extraction as an input feature, designing a training model based on a random forest algorithm, and using the training model to be used for the testing of an independent test set, so as to obtain a chemosensitivity assessment of a patient. If the method provided by the invention is used for screening patients with effective chemotherapy effects before chemotherapy, the method has a significant meaning on cancer therapy.

The invention discloses a kit and a method for detecting 50 tumor-relevant hotspot mutation genes. According to the method, a capture method of 207 hotspot mutation regions of 50 relevant genes (including oncogenes and cancer suppressor genes) and a preparation method of a liquid-phase hybridization library used in capturing are researched aiming at oncology. The method particularly comprises the steps of selecting sequence information of 207 hotspot mutation regions, designing a PCR primer, preparing a biotin labeled liquid-phase hybridization library by virtue of a PCR method, hybridizing the biotin labeled liquid-phase hybridization library with a constructed target genome DNA library, and carrying out high-throughput sequencing and bioinformatics analysis on captured fragments, so as to obtain the mutation condition of nucleic acid sequence sites of a sample. By virtue of the method provided by the invention, high-quality sequencing data can be obtained, the relatively high capturing efficiency and the relatively good uniform capturing of the target sites can be realized, the disadvantages of low efficiency, poor uniformity and the like of solid phase hybridization are solved, and the sequencing cost is greatly lowered.

The present invention addresses the problem of providing malignant stem cells that can be grown in vitro and are useful in cancer therapy research and drug discovery research for cancer therapy, a method for producing same, cancer cells induced from the cells, and use for the cells. Provided are induced malignant stem cells that can be grown in vitro, the induced malignant stem cells being characterized in (1) having at least one type of abnormality selected from among (a) abnormal methylation (hypermethylation or hypomethylation) of a cancer suppressor gene or cancer-related gene region in the endogenous genome DNA, (b) somatic mutation of a cancer suppressor gene in the endogenous genome DNA or somatic mutation of an endogenous cancer-related gene, (c) abnormal expression (increased expression or decreased / lost expression); of an endogenous cancer gene or endogenous cancer suppressor gene, (d) abnormal expression (increased expression or decreased / lost expression) of non-coding RNA such as endogenous cancer-related micro RNA, (e) abnormal expression (increased expression or decreased / lost expression) of an endogenous cancer-related protein, (f) endogenous cancer-related metabolism abnormality (hypermetabolism or hypometabolism), or (g) abnormal endogenous cancer-related carbohydrate; and (2) expressing the POU5F1 gene, NANOG gene, SOX2 gene, and ZFP42 gene.

The invention relates to a fluorescence quantitative PCR (Polymerase Chain Reaction) diagnostic kit for rapid detection of mRNA expression level of a BRCA1 gene. The kit comprises BRCA1gene primer, a reference gene GAPDH primer and a Taqman fluorescence probe. The BRCA1 is an important cancer suppressor gene, and proteins coded by the BRCA1 gene play an important role in DNA damage and repair. A fluorescence quantitative PCR with high sensitivity and specificity is employed to detect the mRNA expression level of BRCA1; and a detection result has substantially increased specificity and sensitivity. The kit provides a novel rapid simple gene diagnostic technique for whether a clinical malignant tumor patient should use platinum chemotherapeutics and antimicrotubular medicaments.

The invention belongs to the technical field of biology and particularly relates to a cancer suppressor gene methylation high-throughput detection kit of the colorectal cancer and application thereof.The kit comprises methylation specific multiplex PCR amplification primers having the sequences shown as SEQ ID NO: 1-20 and label primers of which the sequences are shown as SEQ ID NO: 21-41. According to the invention, the target methylation detection areas of one or more genes can be captured at one time and the methylation mutation sequence information of one or more gene target regions of the sample is obtained, so that the methylation state of the target region can be accurately and effectively analyzed and thus the high-throughput, high-sensitivity and high-accuracy methylation detection on the target gene region becomes the reality. The method further has technical characteristics of low cost, simple and rapid operation and the like; and the sample library construction can be completed only through two rounds of PCR.

The invention discloses application of a cancer suppressor gene FBXW7 in preparation of drugs used for preventing or treating breast tumors, an expression vector and a diagnosis medicine, belonging to the field of medical biotechnology. Specifically, the invention provides application of the cancer suppressor gene FBXW7 in preparation of drugs used for preventing or treating breast tumors, the expression vector constructed from the gene FBXW7 and a vector pcDNA3.1 and a preparation method thereof, and the breast tumor diagnosis medicine at least including a pair of primers capable of specific amplification of the gene FBXW7 and composed of an upstream primer and a downstream primer. Expression of the cancer suppressor gene FBXW7 is closely related to breast cancer molecular subtyping; the cancer suppressor gene FBXW7 has specific low expression in a breast cancer with high grade malignancy and exerts an inhibitory effect on growth of breast cancer cells. Thus, screening of breast cancers with low expression of the gene has significant meaning to prognostic prediction of the breast cancers; and specific recovery of expression of the cancer suppressor gene in breast cancer cells provides a novel approach for targeted individualized treatment of the breast cancers.

The invention discloses a drug carrier for general administration through intravenous injection, a preparation method and technology thereof applied to tumor gene therapy, belonging to the field of tumor targeted therapy. The carrier provided by the invention is a novel liposome formed by DOTAP or other analogues and lecithin or derivatives thereof according to a mole ratio of 20: (7-13), can form a stable composite with bioactive substances, and can directionally and efficiently carry the bioactive substances out of the human body to culture and carry into target cells in the human body. Thecomposite provided by the invention has larger carrying capacity; the particle size is greatly decreased, namely, the particle size is optimized to 200nm and below; high transfection efficiency is kept under the condition of high serum concentration; when the carrier package provided by the invention carries cancer suppressor gene or cell suicide gene DNA and the like, the formed composite can betargeted and carried out of the human body to culture, carried away from the human body and carried into the tumor cells in the human body so as to achieve the purpose of carrying out gene therapy onthe tumor.

The invention relates to a fecal DNA quantitative methylation specific PCR detection kit and applications thereof. The kit comprises (1) three pairs of amplification primers for the quantitative methylation of colon tumor incidence related CpG-islands in a cancer suppressor gene promoter region and three probes; and (2) a PCR reagent for amplification. A PCR amplification product obtained through the kit can analyze the methylation status of gene CpG-islands through a (quantitative methylation specific PCR, qMSP) PCR method. The kit has an efficient CpG-island methylation detection effect. The kit is applicable to the epigenetic mutation detection of colon tumor incidence related cancer suppressor genes in faeces.

The invention relates to a method for establishing a pancreatic cancer model, and belongs to the technical field of the establishment of an animal model. According to the method, a slow virus for over-expressing one cancer gene and simultaneous knocking down two cancer suppressor genes is constructed according to cancer genes and cancer suppressor genes having the maximum mutation rate in human pancreatic cancer in TCGA database, and the slow virus is applied to the pancreas head of a tree shrew through orthotopic injection so as to induce pancreatic cancer of the tree shrew; and specifically, the method comprises the following steps: (1) construction of a slow virus vector; (2) virus packaging, titre determination and in vitro verification; (3) virus injection; and (4) monitoring and pathological investigation of the tree shrew. The method disclosed by the invention has the advantages that the method is short in inducing cycle, high and stable in morbidity, and simple and convenient in operation, and is capable of rapidly and effectively establishing a tree shrew pancreatic cancer model for simulating the genetic mechanism of human pancreatic cancer to the greatest extent; and the pancreatic cancer model is applicable to the research of the pathogenesis of human pancreatic cancer, the exploration of cancer therapy targets and the development of novel antineoplastic drugs, so as to offer a reference for the treatment of human pancreatic cancer.

The invention discloses medical applications of four buxus alkaloids compounds in the preparation of antitumor medicines. Experiment results show that the four compounds KBA01, KBA02, KBA03 and KBR18, under the condition of concentration without toxicity to wild normal mouse embryonic fibroblast cells, can selectively kill mouse tumor cells with tumor specific mutant genes p53 and Ras; accordingly, the compounds are very strong in killing activity to human colon cancer cell strains with p53 mutants, but not strong in killing activity to human wild colon cancer cell strains with p53 mutants; and as shown in a GFP (Green Fluorescence Protein) reporter vector screening system of a gene promoter, the compounds KBA02 and KBA03 can activate a promoter of a cancer suppressor gene p16. The characteristics indicate that the compounds from the four buxus plant origins have application potentials for preparing personalized treatment medicines aiming at the tumor mutant genes p53 and Ras as well as the cancer suppressor gene p16.

Disclosed are a human cancer suppressor gene, a protein encoded therein, an expression vector containing the same and a microorganism transformed with the vector. The cancer suppressor gene of the present invention may be effectively used for diagnosing, preventing and treating human cancers.

The invention discloses a blood plasma specific fragment free DNA (deoxyribonucleic acid) quantitative detection kit comprising the following components: two primer pairs for amplifying TP53 gene fragments of which the lengths are respectively 400bp and 150bp, a primer pair for amplifying a reference gene Beta-actin, and fetal genome DNA, wherein the two primer pairs are consistent in backward primer sites, and the lengths of the amplified TP53 gene fragments are determined by virtue of a forward primer. According to the kit disclosed by the invention, a calibration system is introduced based on a fluorescent quantitative PCR (polymerase chain reaction) technology, the fetal genome DNA is used as background DNA, a house-keeping gene Beta-actin is used as the reference gene, a cancer suppressor gene TP53 is used as a target gene, an amplification primer is designed aiming at different lengths of fragments of the cancer suppressor gene TP53, different lengths of the fragments of the Beta-actin gene and the TP53 gene are synchronously amplified by adopting a real-time fluorescent quantitative PCR process, and the content of free DNA with specific fragment sizes in blood plasma can be quantitatively detected.

The invention discloses a method for establishing a pancreatic cancer model in a wild-type adult mouse through lentiviruses. The method comprises lentiviral vector construction, virus packaging, titerdetermination and in-vitro verification, virus injection, and pathological identification. The method comprises selecting an oncogene Kras with the highest variation rate of the human pancreatic cancer and cancer suppressor genes of Tp53, Cdkn2a and Cdkn2b, overexpressing the oncogene KrasG12D in the same lentiviral vectors, simultaneously, knocking down Tp53, Cdkn2a and Cdkn2b through shRNA, carrying out virus injection, and after 40 days, detecting significant pancreatic tumors in the adult mouse which is killed by the pancreatic cancer. The method has a short induction period and high andstable incidence, is easy to operate and fast builds the adult mouse pancreatic cancer model. The pancreatic cancer model simulates the genetic mechanism of human pancreatic cancer to the maximum extent, can be used to study the pathogenesis of human pancreatic cancer and the screening of new therapeutic drugs and therapeutic target points and provides a reference for the treatment on human pancreatic cancer.

The invention discloses the application of circ-0000423 to preparation or screening of colon cancer drugs. High expression of circ-0000423 is closely related to staging and differentiated degree degrees and prognosis of colon cancer. The higher the expression degree is, the later the illness is, and the worse the differentiation and prognosis are, which indicates that the circ-0000423 is closely related to malignant activity of colorectal cancer. The circ-0000423 is capable of adsorbing cancer suppressor genes miR-519 to promote invasion and metastasis of the colorectal cancer by a mechanism ceRNA. The circ-0000423 can serve as a therapeutic target for preparing or screening medicines for treating colon cancer or inhibiting invasion and metastasis of the colon cancer. The circ-0000423 canserve as a detection target in preparation of a diagnostic reagent for the colorectal cancer. The circ-0000423 can serve as a detection target in preparation of a reagent for predicting staging and differentiated degree degrees or prognosis of the colorectal cancer.

The invention discloses a double-strand small activation RNA (dsLRIG-712) for activating cancer suppressor gene LRIG1 expression in brain glioma U251 cells and and application of double-strand small activation RNA (dsLRIG-712). dsLRIG-712 consists of 21 nucleotide positive-sense strands and antisense strands, two dTdT nucleotides are suspended at the 3'terminal of each strand in a protruding manner, and the other 19 nucleotides are mutually paired. The saRNA molecule can specifically activate expression of the LRIG1 gene, the target gene mRNA and the protein expression level are improved, proliferation and exercise capabilities of brain glioma cells are inhibited, and the purpose of suppressing tumor growth is achieved. Therefore, the saRNA molecule can be used for treating brain glioma.

The present invention discloses acetylation of parkin protein and an application of the parkin protein in preparation of medicines for regulation and control of mitophagy, a histone deacetylase inhibitor is used for inducing the acetylation of the parkin protein, so that a mitophagy level of cells is enhanced and growth of tumor cells is inhibited. A plurality of acetylation sites of the parkin protein are screened by using a protein spectrum technology, the acetylation sites are confirmed to be K129, K220, K349 and K408 through a KR point mutation verification analysis, and parkin-KR mutant plasmids are constructed after multi-site mutation. Functional analysis results show that after parkin mutation, the mitophagy level of the cells is weakened and an anti-tumor effect of a cancer suppressor gene parkin is inhibited, indicating acetylation modification is an important regulation and control mode influencing the parkin function.

The invention discloses a cationic polymer for co-loading drugs and genes and application of the cationic polymer. A constructed cationic PCL-ss-P (GHA-co-PEGMA) polymer is rich in side chains, so that the polymer has good biocompatibility and water solubility; in addition, a shell layer is rich in hydroxy groups, which can promote transmembrane transport of a drug / gene complex and improve the transcription and expression of the genes in cells. Under the condition of higher glutathione, cracking of a main chain in the drug / gene complex is caused, and the release of drugs in polymeric micellesis caused, thereby achieving the purpose of inhibiting tumor cell proliferation. The release of the drugs and the transcription and expression of the genes can be combined to treat the lung cancer, and the drug resistance of anti-cancer drugs in the cells is effectively overcome. The cationic polymer for the co-loading drugs and genes and the application of the cationic polymer have the advantagesthat the used experimental conditions are milder, the structure of the cationic polymer is easy to control, the operation is simple, the raw materials are easy to obtain, purification is easy, and the cationic polymer is suitable for industrial production; therefore, the cationic polymer can be used as a common carrier of the anti-cancer drug and cancer suppressor genes, and has a larger market application prospect in the future.

The invention discloses a genetic therapy breast cancer drug preparation method based on microfluidic chip, which includes that: the method adopts biological molecules as computation medium to compute the cancer-related gene expression through biochemical reaction; when the result meets the requirement, the anti-cancer drug is automatically synthesized and released in targeted manner; the anti-cancer drug is complete suicide gene; the biological molecules used as computation medium are DNA molecules and / or enzyme; the oncogene related to breast cancer includes: C-erbB-2, EGFR, c-myc, ras, int-2, bcl-2, BAG-1, BCSG-2 and survivin; the cancer suppressor gene related to breast cancer includes P53, nm23, PTEN, Rb, P16, P21, CHEK2, BRCA1 and BRCA2. The invention can synthesize and release anti-cancer drugs for breast cancer on specified conditions; and the anti-cancer drugs are complete suicide gene. The method can be combined with the nanometer technology and micromachining technology to help improve the treatment effect.

The invention relates to an application of FHL3 (four and a half LIM domains 3) in the preparation of medicines for treating tumors, in particular to application of FHL3 in the preparation of medicines for adjusting the expression of oncogenes and / or cancer suppressor genes in mammal cells as well as an application of FHL3 in the preparation of medicines for inhibiting the growth of the tumor cells of the mammals. The invention also relates to an expression vector containing the nucleotide sequence of the code FHL3, application of the expression vector in the preparation of medicines for adjusting the representation of cancer genes and / or cancer-inhibiting genes in cells of mammals, as well as application of the expression vector in the preparation of medicines for inhibiting the growth of the tumor cells of the mammals. The expression vector in the invention can effectively inhibit the growth of various human tumor cells, and can adjust the expression of the oncogenes and / or cancer suppressor genes so as to inhibit the growth of various human tumor cells.

The invention discloses a novel purpose of an OCT4B protein isomer. The invention provides an application of OCT4B-265 protein in preparing a product promoting cell apoptosis. The OCT4B-265 protein is (1) or (2) of the following: (1) a protein composed of an amino acid sequence represented by sequence 1 in the sequence list; (2) a protein derived from the sequence 1 and has a same function with the sequence 1, wherein the protein (2) is obtained by that the amino acid sequence represented by the sequence (1) in the sequence list is subjected to substitution and / or deletion and / or addition of one or more amino acid residues. As a result of experiments, the invention identifies specific expression of the OCT4B-265 protein in stem cells for a first time, and discloses the apoptosis-promoting function of the OCT4B-265 protein in cell genotoxic stress response for a first time, wherein the stress response is regulated buy a cancer suppressor gene p53.

The invention discloses a cancer suppressor gene ATOH8 and application of an encoding protein thereof. A novel cancer suppressor gene ATOH8 is found. As proved by in-vivo and in-vitro functional study analysis, the cancer suppressor gene plays an important role in the incidence and development processes of cancers. By using the ATOH8, stem cell differentiation can be facilitated, and the drug tolerance of cancer stem cells to chemotherapeutic medicaments can be lowered. Moreover, a novel effective way is provided for induction of the formation of iPSCs (induced Pluripotent Stem Cells) by means of expression of silent ATOH8. By using the cancer suppressor gene ATOH8, novel diagnosis and treatment methods and a medicament screening platform are provided for neoplastic diseases.

The invention discloses a pharmaceutical composition containing medicinal calcium salt for early preventing colorectal adenoma or colorectal cancer. The pharmaceutical composition contains sodium butyrate and medicinal calcium salt, wherein the mass ratio of the sodium butyrate to elemental calcium in the pharmaceutical composition is (2.47-4.95):1. The pharmaceutical composition disclosed by the invention can reduce cancer genes related to the colorectal cancer and can increase related cancer suppressor genes and signal passages to suppress colorectal cancer cell proliferation and migration capabilities and retard cell growth cycle, thereby achieving the purposes of suppressing the occurrence of the colorectal cancer, lowering the incidence rate of the colorectal cancer of mice, and reducing the tumor volume.

The invention discloses new application of P53 gene mutation and telomere dysfunction, namely, application of a reagent for detecting cancer suppressor gene P53 gene mutation and telomere dysfunction in preparing a reagent for clinical diagnosis of polycystic kidney disease, or the application of P53 gene mutation and telomere dysfunction in screening the therapeutics for the polycystic kidney disease. An experimental result shows that the hybrid descendant of the mice with p53N236S gene mutation and the mice suffering from Werner syndrome (WS) suffers from the polycystic kidney disease so that a novel PKD disease model is acquired. According to the application, the condition that the happening of the polycystic kidney disease possibly is a new phenomenon of abnormal proliferation of kidney cells caused by the combined action of mutation p53 and aging signal is discovered for the first time. Through the discovery, the pathogenesis of the polycystic kidney disease is enriched, and a new biomarker for the clinical diagnosis of the polycystic kidney disease is provided.

The invention belongs to the field of gene treatment, provides a new gene therapy product, and specifically relates to a cationic liposome compound of cancer suppressor gene LKB1 eukaryotic expression plasmid as well as a preparation method and an anti-tumor effect thereof. The gene expression carrier contains genes encoding human LKB1 protein and can express the human LKB1 protein in eukaryotic cells. Based on experiments, the cationic liposome compound of cancer suppressor gene LKB1 eukaryotic expression plasmid, disclosed by the invention, has excellent functions of resisting tumor growth and invasion and metastasis so as to provide a new selection for the tumor treatment.

The invention relates to the application of FHL 1 in preparing medicament for treating tumour, in particular to the application of the FHL 1 in preparing the medicament for regulating the expression of cancer genes and / or cancer suppressor genes in cells of mammals and the application of the FHL 1 in preparing the medicament for restraining the growth of tumour cells of the mammals. The inventionalso relates to an expression carrier containing a nucleotide sequence for coding the FHL 1, the application of the expression carrier in preparing the medicament for regulating the expression of thecancer genes and / or the cancer suppressor genes in the cells of the mammals and the application of the expression carrier in preparing the medicament for restraining the growth of the tumour cells ofthe mammals. The expression carrier can effectively suppress the growth of multiple human tumour cells and restrain the growth of the human tumour cells by regulating the expression of the cancer genes and the cancer suppressor genes.

The invention discloses an application of miRNA-196b as a non-small cell lung cancer molecular marker. It is found for the first time that cancer suppressor gene QKI-5 gene silencing can promote expression of miRNA-196b in lung cancer cells, and the expression of miR-196b can promote the proliferation, migration and cell cycle process of non-small cell lung cancer cells and improve the tumor reproductive capacity in animals by inhibiting the target genes GATA6 and TSPAN12 of the non-small cell lung cancer cells.

The invention specifically relates to a method for transcriptional gene expression regulation by using small double-stranded RNAs, which belongs to the fields of biomedicine and molecular biology. The method comprises the following steps: screening and determining an effect site of a target gene on a genomic DNA sequence; designing specific siRNA or shRNA directed to the effect site; transfectingspecific siRNA or shRNA of a target sequence into nucleus. According to the invention, small double-stranded RNAs, including siRNA, shRNA, chemically or biochemically modified siRNA, shRNA built in related plasmids, etc., are utilized to realize transcriptional gene down-regulation or siliencing, or transcriptional gene up-regulation or activation. The small double-stranded RNAs have a powerful gene regulation function in transcription, particularly in treatment and research of malignant tumors, transcriptional down-regulated cancer genes or up-regulated cancer suppressor genes can perform very effective antitumor action.

The invention relates to the field of medicinal biotechnology, particularly to an application of a new cancer suppressor gene FBP1 in the preparation for a medicine for diagnosing, preventing and treating tumour. The cancer suppressor gene is expressed with a low specificity in a tumour cell and a tumour tissue, and has a function of inhibiting the growth of the tumour cell; therefore, the tumours expressing the cancer suppressor gene with a low specificity are selected, and the expression of the cancer suppressor gene in the tumour cell is specifically recovered. A new method is provided for a tumour targeted therapy.

The invention belongs to the field of treating RB (Retinoblastoma), and particularly relates to application of GSK503 in preparing a drug for treating the RB. In the drug, the final concentration of the GSK503 is greater than or equal to 1 mu M. The GSK503 is a novel EZH2 (Enhancer of Zeste Homolog 2) small-molecule inhibitor, and an applicant experimentally finds that the GSK503 is capable of remarkably inhibiting the growth of the RB, and the methylation degree of H3K27me3 in cells is reduced through inhibiting the EZH2, so that cancer suppressor genes can be in re-expression, and the effect of inhibiting the tumor growth is reached. Effective treatment concentration can be reached when the final concentration of the GSK503 reaches 1 mu M, the use effect of the drug is increased while the concentration is increased, and the growth of the RB can be remarkably inhibited.